

May 31, 2024

The Manager, Listing Department
The National Stock Exchange of India Ltd.
Exchange Plaza, Bandra Kurla Complex,
Bandra (E), Mumbai - 400 051
NSE Symbol: PANACEABIO

BSE Limited
Corporate Relationship Department,
Phiroze Jeejeebhoy Towers,
Dalal Street, Mumbai - 400 001
BSE Scrip Code: 531349

Sub: Disclosure under Regulation 30 of SEBI (Listing Obligations and Disclosures Requirements) Regulations, 2015

Reg: Re-designation of Mr. Ankesh Jain as Whole-time Director in the Company and its wholly owned subsidiary, Panacea Biotec Pharma Limited

Dear Sir/Madam,

Pursuant to Regulation 30 read with Schedule III of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 ('SEBI LODR Regulations'), as amended, we wish to inform you that based on the recommendation of the Nomination and Remuneration Committee, the Board of Directors of Panacea Biotec Limited ("the Company") in its Meeting held on May 30, 2024, approved the re-designation of Mr. Ankesh Jain (DIN:03556647) from Whole-time Director designated as Director Sales & Marketing to Whole-time Director of the Company for the remaining tenure of his Term i.e. from June 01, 2024 to March 31, 2025.

The Board of Directors of the Company's wholly owned subsidiary, Panacea Biotec Pharma Limited ("PBPL") has also re-designated Mr. Ankesh Jain who is currently acting as its non-executive Director, to the position of Whole-time Director w.e.f. June 01, 2024.

Mr. Ankesh Jain is not debarred from holding the office of Whole-time Director in the Company as well as in PBPL, by virtue of any SEBI order or any other such authority.

This is for your kind information and record please.

Thanking you,

Sincerely yours,

for **Panacea Biotec Limited**

Vinod Goel
Group CFO and Head Legal
& Company Secretary